• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SGLT2 inhibitors and the risk of urinary tract infections in patients with heart failure: A pooled analysis examining safety endpoints.

作者信息

Borovac Josip A, Kurir Tina, Mustapic Ivona, Kumric Marko, Bozic Josko, Glavas Duska, D'Amario Domenico

机构信息

Department of Pathophysiology, School of Medicine, University of Split, Split, Croatia.

Clinic for Heart and Vascular Diseases, University Hospital of Split, Split, Croatia.

出版信息

Kardiol Pol. 2022;80(2):198-201. doi: 10.33963/KP.a2021.0172. Epub 2021 Dec 6.

DOI:10.33963/KP.a2021.0172
PMID:34870320
Abstract
摘要

相似文献

1
SGLT2 inhibitors and the risk of urinary tract infections in patients with heart failure: A pooled analysis examining safety endpoints.钠-葡萄糖协同转运蛋白2抑制剂与心力衰竭患者尿路感染风险：一项审查安全性终点的汇总分析
Kardiol Pol. 2022;80(2):198-201. doi: 10.33963/KP.a2021.0172. Epub 2021 Dec 6.
2
Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors: JACC Review Topic of the Week.服用 SGLT2 抑制剂患者的泌尿道感染：JACC 本周综述主题。
J Am Coll Cardiol. 2024 Apr 23;83(16):1568-1578. doi: 10.1016/j.jacc.2024.01.040.
3
Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study.钠-葡萄糖共转运蛋白 2 抑制剂与尿路感染：基于倾向评分匹配的人群队列研究。
Can J Diabetes. 2022 Jun;46(4):392-403.e13. doi: 10.1016/j.jcjd.2021.12.005. Epub 2021 Dec 30.
4
Increased risk of urinary tract infection and pyelonephritis under concomitant use of sodium-dependent glucose cotransporter 2 inhibitors with antidiabetic, antidyslipidemic, and antihypertensive drugs: An observational study.钠-葡萄糖协同转运蛋白2抑制剂与抗糖尿病、抗血脂异常及抗高血压药物联合使用时尿路感染和肾盂肾炎风险增加：一项观察性研究。
Fundam Clin Pharmacol. 2022 Dec;36(6):1106-1114. doi: 10.1111/fcp.12792. Epub 2022 May 6.
5
[Urinary tract infections in patients with type 2 diabetes mellitus with pharmacological glucosuria].2型糖尿病合并药物性糖尿患者的尿路感染
Ter Arkh. 2020 Dec 26;92(11):106-109. doi: 10.26442/00403660.2020.11.000581.
6
Genito Urinary Infection and Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Receiving SGLT2 Inhibitors: Evidence from a Systematic Literature Review of Landmark Randomized Clinical Trial.2 型糖尿病患者接受 SGLT2 抑制剂治疗后的泌尿生殖系统感染和尿路感染：来自标志性随机临床试验系统评价的证据。
Drug Res (Stuttg). 2024 Sep;74(7):307-313. doi: 10.1055/a-2347-9824. Epub 2024 Jul 11.
7
Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus.SGLT2抑制剂在糖尿病患者中的安全性。
Curr Drug Saf. 2019;14(2):87-93. doi: 10.2174/1574886314666190206164647.
8
The risk of genito-urinary infections with sodium-glucose cotransporter-2 inhibitors: duration rather than dose matter?钠-葡萄糖协同转运蛋白2抑制剂导致泌尿生殖系统感染的风险：持续时间而非剂量起关键作用？
Expert Rev Clin Pharmacol. 2024 Aug;17(8):763-764. doi: 10.1080/17512433.2024.2367106. Epub 2024 Jun 13.
9
Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.达格列净治疗 2 型糖尿病患者的安全性汇总分析：来自 IIb/III 期临床试验的安全性数据。
Diabetes Obes Metab. 2018 Mar;20(3):620-628. doi: 10.1111/dom.13124. Epub 2017 Oct 26.
10
Study design and rationale of a dose-ranging trial of LX4211, a dual inhibitor of SGLT1 and SGLT2, in type 2 diabetes inadequately controlled on metformin monotherapy.LX4211 是一种 SGLT1 和 SGLT2 的双重抑制剂，在二甲双胍单药治疗控制不佳的 2 型糖尿病患者中的剂量范围试验的研究设计和原理。
Clin Cardiol. 2013 Jul;36(7):367-71. doi: 10.1002/clc.22125. Epub 2013 Apr 29.

引用本文的文献

1
Update on the Efficacy and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Chronic Diseases: A Systematic Review and Meta-Analysis.钠-葡萄糖协同转运蛋白2抑制剂在慢性病患者中的疗效和安全性最新进展：一项系统评价和荟萃分析
Medicina (Kaunas). 2025 Jan 23;61(2):202. doi: 10.3390/medicina61020202.
2
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence.钠-葡萄糖协同转运蛋白2抑制剂在非糖尿病慢性肾脏病患者中的疗效与安全性：近期证据综述
Kidney Dis (Basel). 2023 Apr 11;9(5):326-341. doi: 10.1159/000530395. eCollection 2023 Oct.
3
The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus.
钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽1受体激动剂在2型糖尿病标准治疗中的安全性概况
Life (Basel). 2023 Mar 20;13(3):839. doi: 10.3390/life13030839.
4
Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and Genital Infections in Patients With Diabetic Mellitus and Concomitant Coronary Artery Disease: A Single-Center Experience.钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂与糖尿病合并冠状动脉疾病患者的生殖器感染：单中心经验
Cureus. 2022 Nov 23;14(11):e31842. doi: 10.7759/cureus.31842. eCollection 2022 Nov.
5
SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice.慢性肾脏病中的钠-葡萄糖协同转运蛋白2抑制剂：从作用机制到临床实践
Biomedicines. 2022 Oct 1;10(10):2458. doi: 10.3390/biomedicines10102458.
6
From Skepticism to Hope: The Evolving Concept of the Initiation and Use of Sodium-Glucose Cotransporter 2 Inhibitors in Hospitalized Patients.从怀疑到希望：住院患者中钠-葡萄糖共转运蛋白 2 抑制剂的起始和使用的概念演变。
Drugs. 2022 Jun;82(9):949-955. doi: 10.1007/s40265-022-01730-2. Epub 2022 Jun 9.